Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FOLH1 | Q04609 | 1/20 | 0.44 |
| ▸ | USP2 | O75604 | 1/20 | 0.42 |
| ▸ | SLCO1B1 | Q9Y6L6 | 1/20 | 0.42 |
| ▸ | PDE4A | P27815 | 1/20 | 0.41 |
| ▸ | GSR | P00390 | 1/20 | 0.40 |
| ▸ | RNPEP | Q9H4A4 | 1/20 | 0.39 |
| ▸ | MMP2 | P08253 | 1/20 | 0.37 |
| ▸ | MMP9 | P14780 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.37 |
| ▸ | GGT1 | P19440 | 1/20 | 0.36 |
| ▸ | CPB2 | Q96IY4 | 8/20 | 0.36 |
| ▸ | SLC6A5 | Q9Y345 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11740613 | 1.00 | FOLH1 (0.44) | FOLH1USP2SLCO1B1PDE4AGSR | |
| SCHEMBL11735016 | 0.84 | PDE4A (0.40) | FOLH1USP2SLCO1B1PDE4AKDM4E | |
| SCHEMBL4100264 | 0.83 | FOLH1 (0.47) | FOLH1GSRRNPEPMMP2MMP9 | |
| SCHEMBL4087629 | 0.83 | FOLH1 (0.47) | FOLH1GSRRNPEPMMP2MMP9 | |
| Hydrochloric Acid SCHEMBL6010125 | 0.81 | FOLH1 (0.46) | FOLH1GSRRNPEPMMP2MMP9 | |
| Hydrochloric Acid SCHEMBL6010135 | 0.81 | FOLH1 (0.46) | FOLH1GSRRNPEPMMP2MMP9 | |
| SCHEMBL11737292 | 0.81 | C3AR1 (0.42) | FOLH1USP2SLCO1B1PDE4AKDM4E | |
| SCHEMBL7225798 | 0.80 | FOLH1 (0.54) | FOLH1GSRRNPEPMMP2MMP9 | |
| SCHEMBL7198299 | 0.80 | FOLH1 (0.54) | FOLH1GSRRNPEPMMP2MMP9 | |
| SCHEMBL11729532 | 0.80 | PDE4A (0.52) | USP2SLCO1B1PDE4AKDM4ELMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2673293-B1 | SURROGATES OF POST-TRANSLATIONALLY MODIFIED PROTEINS AND USES THEREOF | HARVARD COLLEGE (US) | 2020-09-16 | — | — | EP | disclosed |
| US-10309973-B2 | Surrogates of post-translationally modified proteins and uses thereof | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2019-06-04 | — | — | US | disclosed |
| US-20170199201-A2 | SURROGATES OF POST-TRANSLATIONALLY MODIFIED PROTEINS AND USES THEREOF | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2017-07-13 | — | — | US | disclosed |
| US-20170023589-A1 | SURROGATES OF POST-TRANSLATIONALLY MODIFIED PROTEINS AND USES THEREOF | HARVARD COLLEGE (US) | 2017-01-26 | — | — | US | disclosed |
| US-9417248-B2 | Surrogates of post-translationally modified proteins and uses thereof | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2016-08-16 | — | — | US | disclosed |
| US-20140024056-A1 | SURROGATES OF POST-TRANSLATIONALLY MODIFIED PROTEINS AND USES THEREOF | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2014-01-23 | — | — | US | disclosed |
| EP-2673293-A2 | SURROGATES OF POST-TRANSLATIONALLY MODIFIED PROTEINS AND USES THEREOF | President and Fellows of Harvard College (US) | 2013-12-18 | — | — | EP | disclosed |
| WO-2012109538-A2 | SURROGATES OF POST-TRANSLATIONALLY MODIFIED PROTEINS AND USES THEREOF | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2012-08-16 | — | — | WO | disclosed |
| WO-2008137165-A1 | ANTI-GLYCATED CD59 ANTIBODIES AND USES THEREOF | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2008-11-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140024056-A1 | SURROGATES OF POST-TRANSLATIONALLY MODIFIED PROTEINS AND USES THEREOF | CD59, SIGLEC9, CD209 | FOLH1 1893/4885USP2 2725/4885SLCO1B1 2540/4885 |
| US-10309973-B2 | Surrogates of post-translationally modified proteins and uses thereof | CD59, SIGLEC9, CD209 | FOLH1 1893/4885USP2 2725/4885SLCO1B1 2540/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.